Contineum Therapeutics, Inc (CTNM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Contineum Therapeutics, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Contineum Therapeutics, Inc (CTNM) has returned 14.26% so far this year and 87.11% over the past 12 months.

Based on dividend-adjusted daily data since Apr 5, 2024, CTNM's average daily return is +0.11%, while the average monthly return is +1.91%. At this rate, your investment would double in approximately 3.1 years.

Historically, 46% of months were positive and 54% were negative. The best month was Aug 2025 with a return of +77.1%, while the worst month was Apr 2025 at -41.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 10 months.

On a daily basis, CTNM closed higher 46% of trading days. The best single day was Jun 20, 2025 with a return of +30.4%, while the worst single day was Nov 19, 2024 at -16.0%.

Contineum Therapeutics, Inc has an annualized alpha of 19.13%, beta of 0.74, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since April 08, 2024.

• This stock participated in 308.78% of S&P 500 Index downside but only 250.14% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CTNM ranks 72 for risk / return — better than 72% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Contineum Therapeutics, Inc (CTNM) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Contineum Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Contineum Therapeutics, Inc was 84.37%, occurring on May 28, 2025. The portfolio has not yet recovered.

The current Contineum Therapeutics, Inc drawdown is 39.95%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Contineum Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Contineum Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.